1. Acetazolamide-related choroidal effusion and choroidal detachment

   News item 30 September 2023 Pages: 1 - 1

2. Consent for pholocodine products to be revoked in New Zealand

   News item 30 September 2023 Pages: 2 - 2

3. Issues associated with use of Cathejell

   News item 30 September 2023 Pages: 3 - 3

4. Novartis recalls one lot of Sandimmune due to crystals

   News item 30 September 2023 Pages: 4 - 4

5. Delayed ADEs post-COVID-19 vaccination in patients with systemic sclerosis

   Clinical study 30 September 2023 Pages: 5 - 5

6. Durvalumab plus tremelimumab-related AEs

   Clinical study 30 September 2023 Pages: 6 - 6

7. High-dose carboplatin causes hearing loss in most patients

   Clinical study 30 September 2023 Pages: 7 - 7

8. PPIs increase risk of GI irAEs in patients receiving immunotherapy

   Clinical study 30 September 2023 Pages: 8 - 8

9. Risk of solicited AEs after influenza vaccination higher in women

   Clinical study 30 September 2023 Pages: 9 - 9

10. SGLT-2 inhibitor-related genital tract infections and UTIs

    Clinical study 30 September 2023 Pages: 10 - 10

11. Tapentadol has similar incidence of opioid-related ADEs to oxycodone

    Clinical study 30 September 2023 Pages: 11 - 11

12. Undiluted IV push levetiracetam: low incidence of adverse events

    Clinical study 30 September 2023 Pages: 12 - 12

13. Other adverse reaction research

    News item 30 September 2023 Pages: 13 - 13

14. Mitragyna-speciosa

    Case report 30 September 2023 Pages: 14 - 14

15. Abiraterone acetate/enzalutamide/LHRH receptor agonists

    Case report 30 September 2023 Pages: 15 - 15

16. Abiraterone/ginkgo-biloba/ginseng/lovastatin

    Case report 30 September 2023 Pages: 16 - 16

17. Adalimumab/secukinumab

    Case report 30 September 2023 Pages: 17 - 17

18. Adalimumab/ustekinumab/vedolizumab

    Case report 30 September 2023 Pages: 18 - 18

19. Adenosine/diltiazem/metoprolol

    Case report 30 September 2023 Pages: 19 - 19

20. Adenosine/oxytocin

    Case report 30 September 2023 Pages: 20 - 20

21. Alemtuzumab/corticosteroids/tacrolimus

    Case report 30 September 2023 Pages: 21 - 21

22. Alendronic-acid/risedronic-acid/zoledronic-acid

    Case report 30 September 2023 Pages: 22 - 22

23. Alprazolam

    Case report 30 September 2023 Pages: 23 - 23

24. Alprazolam/lidocaine

    Case report 30 September 2023 Pages: 24 - 24

25. Alteplase/streptokinase/tocilizumab

    Case report 30 September 2023 Pages: 25 - 25

26. Amfetamine/ziprasidone

    Case report 30 September 2023 Pages: 26 - 26

27. Amifampridine/antiepileptic-drugs/paracetamol

    Case report 30 September 2023 Pages: 27 - 27

28. Amikacin/cotrimoxazole

    Case report 30 September 2023 Pages: 28 - 28

29. Amiodarone

    Case report 30 September 2023 Pages: 29 - 29

30. Amlodipine

    Case report 30 September 2023 Pages: 30 - 30

31. Ampicillin/sulbactam/meropenem/warfarin

    Case report 30 September 2023 Pages: 31 - 31

32. Analgesics/carbamazepine

    Case report 30 September 2023 Pages: 32 - 32

33. Androgen-receptor-antagonists/radium-223-chloride

    Case report 30 September 2023 Pages: 33 - 33

34. Antibacterials/anti-inflammatories

    Case report 30 September 2023 Pages: 34 - 34

35. Antineoplastics

    Case report 30 September 2023 Pages: 35 - 35

36. Antineoplastics

    Case report 30 September 2023 Pages: 36 - 36

37. Antineoplastics

    Case report 30 September 2023 Pages: 37 - 37

38. Antineoplastics

    Case report 30 September 2023 Pages: 38 - 38

39. Antineoplastics

    Case report 30 September 2023 Pages: 39 - 39

40. Antineoplastics

    Case report 30 September 2023 Pages: 40 - 40

41. Antineoplastics

    Case report 30 September 2023 Pages: 41 - 41

42. Antineoplastics/cefazolin

    Case report 30 September 2023 Pages: 42 - 42

43. Antineoplastics/cobalamin/folic-acid

    Case report 30 September 2023 Pages: 43 - 43

44. Antineoplastics/immunosuppressants

    Case report 30 September 2023 Pages: 44 - 44

45. Antithymocyte-globulin/mycophenolate/prednisone

    Case report 30 September 2023 Pages: 45 - 45

46. Antithymocyte-globulin/tacrolimus

    Case report 30 September 2023 Pages: 46 - 46

47. Antivenin-Inoserp-Pan-Africa

    Case report 30 September 2023 Pages: 47 - 47

48. Antivirals

    Case report 30 September 2023 Pages: 48 - 48

49. Apixaban

    Case report 30 September 2023 Pages: 49 - 49

50. Arsenic

    Case report 30 September 2023 Pages: 50 - 50